- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alphamab Oncology (9966)
Alphamab Oncology stock price live, this page displays HK 9966 stock exchange data. View the 9966 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alphamab Oncology real time stock price chart below.
What Is the Alphamab Oncology Stock Price Today?
The Alphamab Oncology stock price today is 9.09.
What Is the Stock Symbol for Alphamab Oncology?
The stock symbol for Alphamab Oncology is ""9966.""
What Stock Exchange Does Alphamab Oncology Trade On?
Alphamab Oncology is listed and trades on the Hong Kong stock exchange.
Is Alphamab Oncology a Good Stock to Buy?
Determining whether Alphamab Oncology—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9966 quote. (ISIN: KYG0330A1013)
What Is the Alphamab Oncology Stock Price Today?
The Alphamab Oncology stock price today is 9.09.
What Is the Stock Symbol for Alphamab Oncology?
The stock symbol for Alphamab Oncology is ""9966.""
What Stock Exchange Does Alphamab Oncology Trade On?
Alphamab Oncology is listed and trades on the Hong Kong stock exchange.
Is Alphamab Oncology a Good Stock to Buy?
Determining whether Alphamab Oncology—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9966 quote. (ISIN: KYG0330A1013)
Hong Kong
Currency in HKD
9.09
-0.65(-6.67%)
Delayed Data·
Fair Value
An estimate of a Alphamab's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.85
9.74
52 wk Range
2.16
10.78
9966 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
9966 is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Alphamab's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.859.74
52 wk Range
2.1610.78
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
9966 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Alphamab's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.20
Downside
-20.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- NIO (H-Shares) receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alphamab Oncology receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Alphamab Oncology receives Investment Bank Analyst Rating Update
- Investing.com
Pro - NIO (H-Shares) receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Alphamab Oncology Company Profile
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology biologics. The company commercializes KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENQEIDA brand name. Its product pipeline includes KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antiboday that is in Phase III clinical trials for treatment of HER2-positive breast cancer and HER2- positive gastric cancer or gastroesophageal junction cancer; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in Phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; JSKN016, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced malignant solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People’s Republic of China.
Compare 9966 to Peers and Sector
Metrics to compare | 9966 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9966PeersSector | |
|---|---|---|---|---|
P/E Ratio | 52.1x | −26.1x | −0.5x | |
PEG Ratio | 0.29 | 0.56 | 0.00 | |
Price/Book | 4.7x | 7.0x | 2.6x | |
Price / LTM Sales | 13.5x | 22.8x | 3.3x | |
Upside (Analyst Target) | −26.1% | −1.5% | 42.8% | |
Fair Value Upside | Unlock | −15.4% | 6.5% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.20
(-20.82% Downside)
Earnings
Latest Release
Apr 28, 2025
EPS / Forecast
0.21 / --
Revenue / Forecast
466.52M / --
People Also Watch
FAQ
What Stock Exchange Does Alphamab Trade On?
Alphamab is listed and trades on the Hong Kong Stock Exchange stock exchange.
What Is the Stock Symbol for Alphamab?
The stock symbol for Alphamab is "9966."
What Is the Alphamab Market Cap?
As of today, Alphamab market cap is 9.46B.
What Is Alphamab's Earnings Per Share (TTM)?
The Alphamab EPS (TTM) is 0.17.
From a Technical Analysis Perspective, Is 9966 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Alphamab Stock Split?
Alphamab has split 0 times.
How Many Employees Does Alphamab Have?
Alphamab has 420 employees.
What is the current trading status of Alphamab (9966)?
As of 06 Aug 2025, Alphamab (9966) is trading at a price of 9.09, with a previous close of 9.74. The stock has fluctuated within a day range of 8.85 to 9.74, while its 52-week range spans from 2.16 to 10.78.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.